Vorinostat Completed Phase 1 Trials for Childhood Central Nervous System Teratoma / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Medulloblastoma / Unspecified Childhood Solid Tumor, Protocol Specific / Recurrent Childhood Large Cell Lymphoma / Childhood Meningioma / Recurrent Childhood Central Nervous System Embryonal Tumor / Childhood Mixed Glioma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Recurrent Childhood Visual Pathway and Hypothalamic Glioma / Childhood Craniopharyngioma / Childhood Burkitt Lymphoma / Childhood Choroid Plexus Tumor / Recurrent Childhood Small Noncleaved Cell Lymphoma / Childhood Central Nervous System Choriocarcinoma / Recurrent Childhood Cerebral Astrocytoma / Childhood Medulloepithelioma / Childhood Central Nervous System Germ Cell Tumor / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Recurrent Childhood Pineoblastoma / Childhood Oligodendroglioma / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent/Refractory Childhood Hodgkin Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Visual Pathway Glioma / Recurrent Childhood Ependymoma / Childhood Central Nervous System Yolk Sac Tumor / Recurrent Childhood Brain Stem Glioma / Childhood Central Nervous System Mixed Germ Cell Tumor / Childhood Central Nervous System Germinoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor Treatment

clinicaltrials.gov IdentifierTitleDrugs
NCT00994500Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma